West Pharmaceutical Services, Inc. $WST Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 2.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,375 shares of the medical instruments supplier’s stock after selling 600 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in West Pharmaceutical Services were worth $5,552,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in WST. Zions Bancorporation National Association UT acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter worth approximately $25,000. Quarry LP acquired a new stake in West Pharmaceutical Services in the 1st quarter valued at $27,000. First Horizon Advisors Inc. grew its stake in West Pharmaceutical Services by 85.0% in the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 85 shares during the period. Cromwell Holdings LLC grew its stake in West Pharmaceutical Services by 587.5% in the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 188 shares during the period. Finally, Brooklyn Investment Group grew its stake in West Pharmaceutical Services by 83.3% in the 1st quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier’s stock valued at $61,000 after acquiring an additional 125 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Down 3.0%

Shares of WST stock opened at $298.13 on Monday. West Pharmaceutical Services, Inc. has a fifty-two week low of $187.43 and a fifty-two week high of $348.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87. The stock’s fifty day moving average is $259.30 and its two-hundred day moving average is $234.65. The firm has a market capitalization of $21.45 billion, a P/E ratio of 44.17, a PEG ratio of 4.40 and a beta of 1.07.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, topping the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. During the same quarter in the previous year, the firm earned $1.85 EPS. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Research analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft set a $345.00 price target on shares of West Pharmaceutical Services and gave the company a “buy” rating in a research note on Friday. Barclays lifted their price target on shares of West Pharmaceutical Services from $260.00 to $275.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. KeyCorp raised their price objective on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Friday. Finally, Redburn Partners set a $311.00 price objective on West Pharmaceutical Services in a report on Monday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $343.56.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.